



NEWS RELEASE

CareDx to Report Third Quarter 2022 Financial Results

2022-10-26

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-289-0438 for domestic callers or 1-323-794-2423 for international callers. Please reference Conference ID: 2768596. To listen to a live webcast, please visit the investor relations section of CareDx's website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CareDx, Inc.

Investor Relations

Ian Cooney

415-287-2300 x 3550

investor@caredx.com

Source: CareDx, Inc.